Literature DB >> 29440983

Combined pars plana lensectomy/vitrectomy for idiopathic macular hole repair without postoperative prone positioning.

Nicola G Ghazi1, Armand Daccache1, Robert Knape1, James S Tiedeman1.   

Abstract

PURPOSE: The aim of this study is to determine the anatomic and visual outcomes following combined pars plana lensectomy/vitrectomy (CPPLV) as a primary procedure for idiopathic macular hole (MH) without post-operative prone positioning (PPP).
MATERIALS AND METHODS: A retrospective chart review of 42 patients (47 eyes) with MH who underwent CPPLV was performed. No PPP was performed; however, patients were instructed to avoid the supine position during the first postoperative week. The main outcome measures included MH closure rate, best corrected post-operative Snellen visual acuity (BCVA), and procedure complications.
RESULTS: Anatomical closure was achieved in 44 eyes (93.6%). The average BCVA in these eyes improved from 20/203 at baseline to 20/91 post-operatively, with 28 (63.6%) having 20/40 or better. Twenty-eight (59.6%) of the 47 eyes had a BCVA of 20/40 or better post-operatively and 35 (74.5%) eyes improved by at least 2 Snellen lines. Post-operative retinal detachment (RD) was observed in 4 eyes (8.5%) and late reopening of the hole in 4 (9.1%). DISCUSSION: The anatomical and visual outcomes and the RD rate of CPPLV with sulcus intraocular lens implantation without PPP are comparable to those of traditional MH surgery techniques. The main advantages include sparing the patient the inconvenience of PPP and eliminating the need for additional post-vitrectomy cataract extraction procedure.

Entities:  

Year:  2008        PMID: 29440983      PMCID: PMC5798171          DOI: 10.5693/djo.01.2008.016

Source DB:  PubMed          Journal:  Digit J Ophthalmol        ISSN: 1542-8958


  62 in total

1.  [Significance of postoperative face-down positioning after surgery for idiopathic macular holes: consecutive case-control study].

Authors:  P Szurman; F M Di Tizio; B Lafaut; S Aisenbrey; S Grisanti; S Roters; K U Bartz-Schmidt
Journal:  Klin Monbl Augenheilkd       Date:  2000-12       Impact factor: 0.700

2.  Shortening the duration of prone positioning after macular hole surgery- comparison between 1-week and 1-day prone positioning.

Authors:  Takako Isomae; Yukihiro Sato; Hiroyuki Shimada
Journal:  Jpn J Ophthalmol       Date:  2002 Jan-Feb       Impact factor: 2.447

3.  Intraretinal silicone oil vacuoles after macular hole surgery with internal limiting membrane peeling.

Authors:  Juliet Chung; Richard Spaide
Journal:  Am J Ophthalmol       Date:  2003-10       Impact factor: 5.258

4.  Late reopening of successfully treated macular holes.

Authors:  M Paques; P Massin; P Y Santiago; A C Spielmann; J F Le Gargasson; A Gaudric
Journal:  Br J Ophthalmol       Date:  1997-08       Impact factor: 4.638

5.  Duration of face-down positioning after macular hole surgery: a comparison between 1 week and 3 days.

Authors:  Jørgen Krohn
Journal:  Acta Ophthalmol Scand       Date:  2005-06

6.  Combined phacoemulsification and pars plana vitrectomy for macular hole treatment.

Authors:  Ioannis P Theocharis; Anastassia Alexandridou; Nasser Jadidi Gili; Zoran Tomic
Journal:  Acta Ophthalmol Scand       Date:  2005-04

7.  Macular hole surgery using thrombin-activated fibrinogen and selective removal of the internal limiting membrane.

Authors:  T W Olsen; P Sternberg; A Capone; D F Martin; J I Lim; H E Grossniklaus; T M Aaberg
Journal:  Retina       Date:  1998       Impact factor: 4.256

8.  Vision-threatening complications of surgery for full-thickness macular holes. Vitrectomy for Macular Hole Study Group.

Authors:  A S Banker; W R Freeman; J W Kim; D Munguia; S P Azen
Journal:  Ophthalmology       Date:  1997-09       Impact factor: 12.079

9.  Posterior segment complications after vitrectomy for macular hole.

Authors:  S S Park; D M Marcus; J S Duker; R D Pesavento; T M Topping; A R Frederick; D J D'Amico
Journal:  Ophthalmology       Date:  1995-05       Impact factor: 12.079

10.  Comparison of recombinant transforming growth factor-beta-2 and placebo as an adjunctive agent for macular hole surgery.

Authors:  J T Thompson; W E Smiddy; G A Williams; R N Sjaarda; H W Flynn; R R Margherio; G W Abrams
Journal:  Ophthalmology       Date:  1998-04       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.